bimekizumab
Showing 1 - 25 of 29
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis Trial (Placebo, Bimekizumab)
Not yet recruiting
- Chronic Plaque Psoriasis
- Moderate to Severe Chronic Plaque Psoriasis
- Placebo
- Bimekizumab
- (no location specified)
Aug 21, 2023
Psoriasis Vulgaris, Active Psoriatic Arthritis Trial (Bimekizumab)
Not yet recruiting
- Psoriasis Vulgaris
- Active Psoriatic Arthritis
- Bimekizumab
- (no location specified)
Aug 10, 2022
Healthy Study Participants Trial in Glendale, Berlin (bimekizumab)
Active, not recruiting
- Healthy Study Participants
- bimekizumab
-
Glendale, California
- +1 more
Sep 20, 2022
Chronic Plaque Psoriasis Trial in Worldwide (Bimekizumab, Placebo)
Completed
- Chronic Plaque Psoriasis
- Bimekizumab
- Placebo
-
Bexley, Ohio
- +7 more
Sep 30, 2022
Moderate to Severe Plaque Psoriasis Trial in Worldwide (bimekizumab)
Active, not recruiting
- Moderate to Severe Plaque Psoriasis
- bimekizumab
-
Indianapolis, Indiana
- +10 more
Aug 19, 2022
Moderate to Severe Plaque Psoriasis Trial in Korea, Republic of (bimekizumab, Placebo)
Active, not recruiting
- Moderate to Severe Plaque Psoriasis
- bimekizumab
- Placebo
-
Bucheon-si, Korea, Republic of
- +8 more
Jul 28, 2022
Chronic Plaque Psoriasis Trial in Worldwide (Bimekizumab)
Completed
- Chronic Plaque Psoriasis
- Bimekizumab
-
High Point, North Carolina
- +9 more
Mar 3, 2022
Healthy Volunteers Trial in Harrow (Bimekizumab)
Completed
- Healthy Volunteers
- Bimekizumab
-
Harrow, United Kingdom(unnamed)
Aug 25, 2021
Healthy Study Participants Trial in Berlin (Bimekizumab)
Terminated
- Healthy Study Participants
- Bimekizumab
-
Berlin, GermanyUp0068 001
Aug 12, 2021
Chronic Plaque Psoriasis Trial in Worldwide (Bimekizumab, Placebo)
Completed
- Chronic Plaque Psoriasis
- Bimekizumab
- Placebo
-
Los Angeles, California
- +35 more
Sep 27, 2022
Ankylosing Spondylitis Trial in Worldwide (Bimekizumab)
Completed
- Ankylosing Spondylitis
- Bimekizumab
-
Sarasota, Florida
- +49 more
Nov 17, 2022
Hidradenitis Suppurativa Trial in Worldwide (Bimekizumab, Adalimumab, Placebo)
Completed
- Hidradenitis Suppurativa
- Bimekizumab
- +2 more
-
Los Angeles, California
- +30 more
Mar 14, 2022
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis Trial in Worldwide (Bimekizumab, Secukinumab, Placebo)
Active, not recruiting
- Chronic Plaque Psoriasis
- Moderate to Severe Chronic Plaque Psoriasis
- Bimekizumab
- +2 more
-
Santa Ana, California
- +76 more
Jan 25, 2023
Hidradenitis Suppurativa Trial in Worldwide (Bimekizumab, Placebo)
Active, not recruiting
- Hidradenitis Suppurativa
- Bimekizumab
- Placebo
-
Birmingham, Alabama
- +87 more
Feb 2, 2023
Psoriatic Arthritis Trial in Worldwide (Bimekizumab)
Completed
- Psoriatic Arthritis
- Bimekizumab
-
Lexington, Kentucky
- +36 more
Oct 28, 2021
Hidradenitis Suppurativa Trial in Worldwide (Bimekizumab, Placebo)
Completed
- Hidradenitis Suppurativa
- Bimekizumab
- Placebo
-
Fountain Valley, California
- +90 more
Nov 8, 2022
Nonradiographic Axial Spondyloarthritis Trial in Worldwide (Bimekizumab, Placebo)
Active, not recruiting
- Nonradiographic Axial Spondyloarthritis
- Bimekizumab
- Placebo
-
Mesa, Arizona
- +82 more
Aug 23, 2022
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis Trial in Worldwide (Bimekizumab,
Completed
- Chronic Plaque Psoriasis
- +2 more
- Bimekizumab
- Placebo
-
San Diego, California
- +76 more
Jul 15, 2022
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis Trial in Canada, United States (Bimekizumab)
Completed
- Chronic Plaque Psoriasis
- Moderate to Severe Chronic Plaque Psoriasis
- Bimekizumab
-
Phoenix, Arizona
- +38 more
Jan 6, 2022
Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa Trial in Worldwide (Bimekizumab)
Enrolling by invitation
- Axial Spondyloarthritis
- +2 more
- Bimekizumab
-
Glendale, Arizona
- +72 more
Mar 24, 2022
Healthy Volunteers Trial in San Antonio (Bimekizumab)
Completed
- Healthy Volunteers
- Bimekizumab
-
San Antonio, TexasUp0034 001
Sep 16, 2020
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis Trial in Worldwide (Bimekizumab,
Completed
- Chronic Plaque Psoriasis
- +2 more
- Bimekizumab
- +2 more
-
Phoenix, Arizona
- +104 more
Jul 15, 2022
Psoriatic Arthritis Trial in Worldwide (Bimekizumab, Placebo)
Completed
- Psoriatic Arthritis
- Bimekizumab
- Placebo
-
Phoenix, Arizona
- +92 more
Mar 14, 2022
Hidradenitis Suppurativa Trial in Worldwide (Bimekizumab)
Enrolling by invitation
- Hidradenitis Suppurativa
- Bimekizumab
-
Birmingham, Alabama
- +136 more
Jul 26, 2022